About
Small molecule Beta catenin inhibitors
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
226
By Phase
PHASE1: 2PHASE1/PHASE2: 1
By Status
NOT_YET_RECRUITING: 1RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07144254Collaborator
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
PHASE1Not yet recruiting
24 participants
Started: Oct 31, 2025 · Completed: May 31, 2028
NCT05797805Lead Sponsor
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
PHASE1/PHASE2Recruiting
178 participants
Started: Sep 13, 2023 · Completed: Jun 30, 2026
NCT03459469Lead Sponsor
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
PHASE1Completed
24 participants
Started: Jul 15, 2018 · Completed: May 1, 2022
Locations (1)
Headquarters
Houston, TX, United States
Map
Loading map...